Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2216684 adjunctive to SSRI for prevention of symptom reemergence in major depressive disorder
KCT0000995Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of edivoxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started Jul 2011; status: completed.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on KCT0000995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000995.